請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/94959完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 方啓泰 | zh_TW |
| dc.contributor.advisor | Chi-Tai Fang | en |
| dc.contributor.author | 林申樺 | zh_TW |
| dc.contributor.author | Shen-Hua Lin | en |
| dc.date.accessioned | 2024-08-21T16:55:15Z | - |
| dc.date.available | 2024-08-22 | - |
| dc.date.copyright | 2024-08-21 | - |
| dc.date.issued | 2024 | - |
| dc.date.submitted | 2024-07-26 | - |
| dc.identifier.citation | [1] Sheahan TP, Sims AC, Zhou S, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med 2020; 12(541).
[2] First oral antiviral for COVID-19, Lagevrio (molnupiravir), approved by MHRA. https://products.mhra.gov.uk/ (accessed June 1 2024). [3] Zhou S, Hill CS, Sarkar S, et al. β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells. J Infect Dis 2021; 224(3): 415-9. [4] WHO Guidelines Approved by the Guidelines Review Committee. Therapeutics and COVID-19: living guideline. Geneva: World Health Organization; 2022. [5] COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/ (accessed June 1 2024). [6] Sun M, Lai H, Huang J, et al. Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients. J Antimicrob Chemother 2023; 78(9): 2131-9. [7] Tian F, Feng Q, Chen Z. Efficacy and Safety of Molnupiravir Treatment for COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Int J Antimicrob Agents 2023; 62(2): 106870. [8] Malin JJ, Weibel S, Gruell H, Kreuzberger N, Stegemann M, Skoetz N. Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis. J Antimicrob Chemother 2023; 78(7): 1586-98. [9] Gao Y, Liu M, Li Z, Xu J, Zhang J, Tian J. Molnupiravir for treatment of adults with mild or moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials. Clin Microbiol Infect 2023; 29(8): 979-99. [10] Huang PY, Liu TH, Wu JY, Tsai YW, Lai CC. Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID-19: A systematic review and meta-analysis of randomized control trials. J Med Virol 2023; 95(3): e28621. [11] Huang C, Lu TL, Lin L. Real-World Clinical Outcomes of Molnupiravir for the Treatment of Mild to Moderate COVID-19 in Adult Patients during the Dominance of the Omicron Variant: A Meta-Analysis. Antibiotics (Basel) 2023; 12(2). [12] Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med 2022; 386(6): 509-20. [13] Butler CC, Hobbs FDR, Gbinigie OA, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet 2023; 401(10373): 281-93. [14] Park HR, Yoo M-G, Kim JM, Bae SJ, Lee H, Kim J. Effectiveness of Molnupiravir Treatment in Patients with COVID-19 in Korea: A Propensity Score Matched Study. Infection & Chemotherapy 2023; 55(4): 490. [15] Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. Lancet 2022; 400(10359): 1213-22. [16] Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6(7): e1000097. [17] Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928. [18] Kamel AM, Sobhy M, Magdy N, Sabry N, Farid S. Anticoagulation outcomes in hospitalized Covid-19 patients: A systematic review and meta-analysis of case-control and cohort studies. Rev Med Virol 2021; 31(3): e2180. [19] Reeves BC DJ, Higgins JPT, Shea B, Tugwell P, Wells GA. Chapter 24: Including non-randomized studies on intervention effects. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from www.training.cochrane.org/handbook. [20] Zhang J, Yu KF. What's the Relative Risk?A Method of Correcting the Odds Ratio in Cohort Studies of Common Outcomes. JAMA 1998; 280(19): 1690-1. [21] Shor E, Roelfs D, Vang ZM. The “Hispanic mortality paradox” revisited: Meta-analysis and meta-regression of life-course differentials in Latin American and Caribbean immigrants' mortality. Soc Sci Med 2017; 186: 20-33. [22] Cooper H, Hedges LV, Valentine JC. The handbook of research synthesis and meta-analysis: Russell Sage Foundation; 2019. [23] Friedrich JO, Adhikari NKJ, Beyene J. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol 2007; 7(1): 5. [24] Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I² index? Psychol Methods 2006; 11(2): 193-206. [25] Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. BMJ 2011; 342: d549. [26] Sterne JAC, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011; 343: d4002. [27] Schünemann HJ, Brennan S, Akl EA, et al. The development methods of official GRADE articles and requirements for claiming the use of GRADE – A statement by the GRADE guidance group. J Clin Epidemiol 2023; 159: 79-84. [28] A Prospective, Randomized, Multicenter, Open Label, Parallel Group Study To Evaluate Safety And Efficacy Of Oral Molnupiravir As Add On To Standard Of Care For Treatment Of Mild Patients With Covid-19 Disease. CTRI/2021/06/033938. Clinical Trials Registry India [Internet]; 2021. [29] A Phase III, Multicentric, Prospective, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Molnupiravir in Adult Indian Patients with Moderate COVID 19. CTRI/2021/05/033736. Clinical Trials Registry India [Internet]; 2021. [30] A Phase 3, Prospective, Open Label, Randomized, Multicenter, Parallel Study to evaluate the efficacy and safety of Molnupiravir capsules when administered along with Standard of Care compared to Standard of Care alone in Indian patients with Moderate COVID-19 disease. CTRI/2021/08/035424. Clinical Trials Registry India [Internet]; 2021. [31] Optimus announces Interim Clinical Results from Phase III Clinical Trials of Molnupiravir conducted in India. The Print 2021. [32] Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Professionals. April 12, 2024. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html#print (accessed June 19 2024). [33] Deeks JJ HJ, Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from www.training.cochrane.org/handbook. [34] Brookhart MA, Wyss R, Layton JB, Stürmer T. Propensity score methods for confounding control in nonexperimental research. Circ Cardiovasc Qual Outcomes 2013; 6(5): 604-11. [35] Rücker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I(2) in assessing heterogeneity may mislead. BMC Med Res Methodol 2008; 8: 79. | - |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/94959 | - |
| dc.description.abstract | 背景
由於現有隨機分派試驗和納入隨機分派試驗的統合分析結果不一致，molnupiravir用於治療新型冠狀病毒疾病的角色仍不明確。本研究目的是透過納入隨機分派試驗和真實世界研究數據進行系統回顧和統合分析，以評估molnupiravir在不同患者群體中的有效性。 方法 本研究檢索了Medline、Embase、Cochrane Register of Clinical Trials和 ClinicalTrials.gov等資料庫，截至2024年6月9日，納入molnupiravir用於治療輕度至中度新冠肺炎且具重症風險非住院成年人的研究，研究類型包含隨機分派試驗及觀察性研究。分析使用隨機效應模型進行統合分析，研究終點為28天住院率、死亡率、不良事件，以及3個月和6個月的有效性結果，估計值使用校正風險比 (adjusted risk ratio, aRRs)。本研究已在PROSPERO (CRD42023477918) 註冊。 結果 本研究共納入33篇研究 (包含1,592,214名參與者)，其中11篇為隨機分派試驗、22篇為世代研究。隨機分派試驗的統合分析結果顯示，molnupiravir有效降低平均年齡<45歲患者的住院風險，但並未顯著降低平均年齡45-57歲患者的住院風險 (RR 0·55; 95% CI 0·36–0·84 vs 1·06; 95% CI 0·81–1·39，次組差異檢定P=0.01)；世代研究的統合分析結果顯示，molnupiravir有效降低平均年齡≥73歲患者的住院風險，但並未顯著降低平均年齡62-72歲患者的住院風險 (RR 0·62; 95% CI 0·49–0·78 vs 0·90; 95% CI 0·76–1·05，次組差異檢定P=0·01)。然而，molnupiravir在隨機分派試驗 (RR 0·35; 95% CI 0·12–0·98) 和世代研究 (RR 0·39; 95% CI 0·30–0·51) 中均有效降低28天死亡風險，且未增加不良反應事件。死亡率降低的效果在追蹤3個月 (RR 0·47; 95% CI 0·23–0·95) 和6個月 (RR 0·62; 95% CI 0·52–0·74) 仍然顯著。 結論 Molnupiravir不能有效降低平均年齡45至72歲輕度至中度新冠肺炎患者的住院風險，但可以降低28天、3個月和6個月的死亡風險。 | zh_TW |
| dc.description.abstract | Background
The role of molnupiravir in the treatment of coronavirus disease 2019 (COVID-19) remains unclear, as randomised controlled trials (RCTs) and RCT-based meta-analyses have yielded conflicting results. Methods We conducted a systematic review and meta-analysis of data from both RCTs and real-world studies to evaluate the effectiveness of molnupiravir in preventing COVID-19-related hospitalisation or death (PROSPERO #CRD42023477918). The search included studies up to 9 June 2024. Random effects models were used to estimate the pooled effect size. Findings A total of 33 studies were included, comprising 30,345 participants from 11 RCTs and 1,561,869 participants from 22 cohort studies. In RCTs, molnupiravir was effective in preventing 28-day hospitalisation in younger patients (mean age 35-45 years) but not in older patients (mean age 45-57 years) (RR 0·55; 95% CI 0·36–0·84 vs 1·06; 95% CI 0·81–1·39, test for subgroup difference P=0.01). In contrast, cohort studies showed a benefit in older patients (mean age 73-83 years) but not in those aged 62-72 years (RR 0·62; 95% CI 0·49–0·78 vs 0·90; 95% CI 0·76–1·05, test for subgroup difference P=0·01). However, molnupiravir significantly decreased 28-day mortality risk in both RCTs (RR 0·35; 95% CI 0·12–0·98, I2 0%) and cohort studies (RR 0·39; 95% CI 0·30–0·51, I2 90%), without increasing adverse events. This mortality risk reduction persisted at 3 months (RR 0·47; 95% CI 0·23–0·95, I2 93%) and 6 months (RR 0·62; 95% CI 0·52–0·74, I2 0%). Interpretation The synthesis of evidence from RCTs and real-world studies indicates that while molnupiravir may not be effective in preventing hospitalisation in patient groups with a mean age of 45-72 years, it significantly decreases COVID-19-related mortality risk at 28 days, 3 months, and 6 months. | en |
| dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2024-08-21T16:55:15Z No. of bitstreams: 0 | en |
| dc.description.provenance | Made available in DSpace on 2024-08-21T16:55:15Z (GMT). No. of bitstreams: 0 | en |
| dc.description.tableofcontents | 摘要 i
Abstract iii Research in Context 1 Introduction 2 Methods 3 Results 6 Discussion 10 Figures 14 Tables 19 Reference 23 Appendix 27 | - |
| dc.language.iso | en | - |
| dc.subject | 住院 | zh_TW |
| dc.subject | 莫納皮拉韋 (molnupiravir) | zh_TW |
| dc.subject | 死亡 | zh_TW |
| dc.subject | 新冠肺炎 | zh_TW |
| dc.subject | hospitalisation | en |
| dc.subject | mortality | en |
| dc.subject | COVID | en |
| dc.subject | molnupiravir | en |
| dc.title | Molnupiravir 預防 COVID-19 相關住院或死亡的成效：一項包含1,592,214名患者的隨機對照試驗和真實世界研究的系統性回顧與統合分析 | zh_TW |
| dc.title | Effectiveness of Molnupiravir to Prevent COVID-19-related Hospitalisation or Death: A Systematic Review and Meta-analysis of Randomised Controlled Trials and Real-world Studies Involving 1,592,214 Patients | en |
| dc.type | Thesis | - |
| dc.date.schoolyear | 112-2 | - |
| dc.description.degree | 碩士 | - |
| dc.contributor.oralexamcommittee | 杜裕康;王振泰 | zh_TW |
| dc.contributor.oralexamcommittee | Yu-Kang Tu;Jann-Tay Wang | en |
| dc.subject.keyword | 莫納皮拉韋 (molnupiravir),新冠肺炎,住院,死亡, | zh_TW |
| dc.subject.keyword | molnupiravir,COVID,hospitalisation,mortality, | en |
| dc.relation.page | 46 | - |
| dc.identifier.doi | 10.6342/NTU202402253 | - |
| dc.rights.note | 同意授權(限校園內公開) | - |
| dc.date.accepted | 2024-07-29 | - |
| dc.contributor.author-college | 公共衛生學院 | - |
| dc.contributor.author-dept | 流行病學與預防醫學研究所 | - |
| dc.date.embargo-lift | 2029-07-24 | - |
| 顯示於系所單位： | 流行病學與預防醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-112-2.pdf 未授權公開取用 | 2.49 MB | Adobe PDF | 檢視/開啟 |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。